Magainin-2

Magainin-2 is one of the most extensively studied antimicrobial peptides, isolated from the skin of the African clawed frog Xenopus laevis. Its discovery in 1987 catalyzed the field of antimicrobial peptide research and established the paradigm of cationic amphipathic peptides as natural antibiotics.

The 23-amino acid peptide is unstructured in aqueous solution but adopts an amphipathic alpha-helix upon contact with membranes. This membrane-induced folding creates a structure with cationic and hydrophobic faces that enables selective interaction with bacterial membranes (negatively charged) over mammalian membranes (zwitterionic).

Magainin-2's antimicrobial mechanism involves the toroidal pore model, where multiple peptide molecules insert into the membrane with their hydrophobic faces interacting with lipid tails while inducing positive membrane curvature. This creates water-filled pores that dissipate membrane potential and cause cell death.

Despite promising preclinical results, magainin analogs (pexiganan) failed to achieve FDA approval for diabetic foot ulcer treatment, illustrating challenges in translating antimicrobial peptides to clinical use. Nevertheless, magainin-2 remains a foundational model compound for antimicrobial peptide research and design optimization.